000			nab a22 7a 4500
999			_c16572 _d16572
003			PC16572
005			20210811104306.0
008			210803b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9882 _aCastellano, Daniel _eOncología Médica
245	0	0	_aRecommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma. _h[revisión]
260			_bCancer chemotherapy and pharmacology, _c2014
300			_a73(6):1095-107.
500			_aFormato Vancouver: García Del Muro X, Gallardo E, García Carbonero I, Laínez N, José Méndez M, Maroto P et al. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2014 Jun;73(6):1095-107.
501			_aPMID: 24531612
504			_aContiene 58 referencias
520			_aClear-cell renal cell carcinoma (RCC) is the most common kidney cancer. New treatment options of localized RCC recently incorporated include laparoscopic surgery, nephron-sparing surgery, ablative techniques and active surveillance. But 50 % of patients may develop disease recurrence attributable to subclinical metastases. In these cases, and considering the low benefits of chemotherapy, new targeted therapies such as tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors have been developed as first- and second-line treatment. Both sunitinib and pazopanib are TKIs that constitute the first-line treatment option in patients with metastatic RCC. As second-line treatment, sequential therapy with a second TKI or a mTOR inhibitor is recommended. This review has collected together a series of recommendations issued by the Spanish Oncology Genitourinary Group with the aim of facilitating the treatment of these patients. Each recommendation is accompanied by the level of evidence and grade of recommendation on the basis of the available data.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16572.pdf _ySolicitar documento
942			_2ddc _cREV _n0